The broader medical and health products industry continues to evolve under the dual pressures of regulatory oversight and the need for differentiated, clinically validated solutions. Across pharmaceuticals, nutritional supplements and animal health, companies are increasingly focusing on niche markets, specialty products and science-backed innovation rather than broad commoditized offerings.Recent industry trends underscore a growing emphasis on targeted therapies and specialty products for clearly defined ...

Financial Data and Key Metrics Changes - Product sales for Q4 2025 were $7.6 million, a decrease of 1.6% compared to Q4 2024, with domestic sales growing 8.7% to $7 million [12][13] - Full-year product sales for 2025 totaled $27.6 million, reflecting a growth of 4.3% compared to 2024 [14] - A non-cash impairment write-down of approximately $2.9 million is expected due to the shift in strategy regarding Re-Tain [15] Business Line Data and Key Metrics Changes - The First Defense product line saw a significant growth of 41.3% in Q4 2025 compared to Q4 2024, indicating strong demand [5] - There is a noted shift towards the Tri-Shield product within the First Defense suite, reflecting a migration from Dual-Force products [14] Market Data and Key Metrics Changes - Domestic sales showed an increase of 8.7%, while international sales declined by 52.6% in Q4 2025, primarily due to order timing in Canada [13][14] - The total addressable market for First Defense is estimated to be approximately $900 million worldwide, driven by increased calf values and the need for early-life calf health solutions [8] Company Strategy and Development Direction - The company is shifting its strategic focus to prioritize First Defense, pausing investments in Re-Tain due to regulatory challenges and a high confidence in First Defense's growth potential [6][7] - Plans include expanding the sales team by 50% and creating two new U.S. sales territories to drive growth in First Defense [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the future sales and profit growth potential of First Defense, emphasizing the importance of operational excellence and capacity expansion [17][18] - The company is optimistic about the ongoing investigational studies for Re-Tain, which are expected to provide valuable data for future partnerships [41] Other Important Information - The company is repurposing manufacturing assets from Re-Tain to support First Defense, which is expected to enhance production capacity without significant additional capital [6][11] - A write-down of approximately $600,000 is planned for inventory deemed unsuitable for requirements [16] Q&A Session Summary Question: Impact of regional pathogens on foreign sales development - Management acknowledged the complexity of international sales and the need for experienced personnel to navigate product requirements and market strategies [22] Question: Explanation for contract manufacturer's failure to comply with FDA requirements - Management declined to provide details but confirmed that the Incomplete Letter from the FDA was solely due to issues with the contract manufacturer [24][25] Question: Timeline for securing a strategic partner for Re-Tain - Management expressed confidence in the product's capabilities and indicated that they would seek partnerships after completing investigational studies in 2026 [28][41] Question: Clarity on the self-imposed milk discard period for Re-Tain - Management clarified that the discard period is necessary to avoid impacting cheese production, but it is still less than competitors' requirements [47][48] Question: Explanation for exceeding sales expectations - Management attributed the sales exceeding expectations to effective management practices and a strong commercial team, despite complexities from previous backorder situations [54][55]

Financial Data and Key Metrics Changes - The company reported product sales for Q4 2025 at $7.6 million, a decrease of 1.6% compared to Q4 2024, primarily due to a previous backorder situation that inflated sales in the prior year [12][13] - Domestic sales grew by 8.7% year-over-year to $7 million, while international sales declined by 52.6% due to order timing in Canada [13][14] - Full-year product sales for 2025 totaled $27.6 million, reflecting a 4.3% increase compared to 2024 [14] Business Line Data and Key Metrics Changes - The First Defense product line saw significant growth, with Tri-Shield experiencing a 41.3% increase in Q4 2025 compared to Q4 2024, indicating a shift from Dual-Force products [5][14] - The company is focusing on increasing manufacturing output for First Defense, achieving over a 15% increase in lyophilization output in 2025, with expectations for similar growth in 2026 [9][18] Market Data and Key Metrics Changes - The newborn calf market has evolved, with calf values increasing significantly, leading to a greater economic emphasis on early-life calf health and survival [8] - The total addressable market for scour protection is estimated at approximately $900 million worldwide, indicating substantial growth potential for First Defense products [8] Company Strategy and Development Direction - The company is shifting its strategic focus to First Defense, pausing investments in Re-Tain due to an Incomplete Letter from the FDA, which has delayed the product's approval process [6][7] - The strategy includes expanding the sales team by 50% and creating two new U.S. sales territories to drive growth in First Defense [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of First Defense, citing the need for increased focus and execution to capitalize on market opportunities [6][9] - The company plans to complete investigational studies for Re-Tain to prepare for potential partnerships, emphasizing that manufacturing in-house is not the best use of resources [11][41] Other Important Information - A non-cash impairment write-down of approximately $2.9 million is expected due to the shift in strategy regarding Re-Tain [15] - An estimated write-down of $600,000 for inventory deemed unsuitable for requirements has been planned [16] Q&A Session Summary Question: Impact of regional pathogens on foreign sales development - Management acknowledged the complexity of international sales and the need for experienced personnel to navigate product requirements and market strategies [21][22] Question: Explanation for contract manufacturer's failure to comply with FDA requirements - Management declined to provide details but confirmed that the Incomplete Letter was solely due to issues with the contract manufacturer [24][25] Question: Timeline for securing a strategic partner for Re-Tain - Management expressed confidence in the product's capabilities and indicated that they would seek partners after completing investigational studies in 2026 [28][41] Question: Clarity on the self-imposed milk discard period for Re-Tain - Management clarified that the discard period is necessary to prevent impact on cheese manufacturing processes, although it is less than competitors [46][48] Question: Explanation for exceeding sales expectations - Management attributed the sales exceeding expectations to effective management practices and a strong commercial team, despite complexities from previous backorder situations [52][55]

Financial Data and Key Metrics Changes - The company reported product sales for Q4 2025 at $7.6 million, a decrease of 1.6% compared to Q4 2024, with domestic sales growing 8.7% to $7 million [11][12] - Full-year product sales for 2025 totaled $27.6 million, reflecting a 4.3% increase compared to 2024 [12] - The company experienced a significant decline in international sales, particularly in Canada, which dropped 52.6% year-over-year in Q4 [12] Business Line Data and Key Metrics Changes - The First Defense product line saw a notable shift towards Tri-Shield, indicating a migration from Dual-Force products and attracting new dairy and beef customers [12] - Manufacturing output for the key bottleneck process, lyophilization, increased by more than 15% in 2025, with expectations for similar growth in 2026 [8][17] Market Data and Key Metrics Changes - The newborn calf market has evolved, with calf values increasing significantly, now worth approximately $1,300 on day one of life compared to roughly $200 in 2003, raising the economic stakes for early-life calf health [7] - The total addressable market for scour protection is estimated to be around $900 million worldwide [7] Company Strategy and Development Direction - The company is shifting its strategic focus to First Defense, pausing investment in Re-Tain due to an Incomplete Letter from the FDA regarding its new animal drug application [4][6] - The strategy includes expanding the sales team by 50% and creating two new U.S. sales territories to drive growth [16] - The company aims to repurpose manufacturing assets from Re-Tain to support First Defense, enhancing operational efficiency [10][14] Management's Comments on Operating Environment and Future Outlook - Management expressed high confidence in the future sales and profit growth potential of the First Defense business, justifying the strategic shift [5][6] - The company is focused on operational excellence to ensure consistent supply and quality of products, with plans to optimize manufacturing processes [16][17] Other Important Information - A non-cash impairment write-down of approximately $2.9 million is expected due to the shift in strategy regarding Re-Tain [14] - An estimated write-down of $600,000 was taken for inventory deemed unsuitable for requirements [15] Q&A Session Summary Question: Impact of regional pathogens on foreign sales development - Management acknowledged the complexity of international sales and the need for expertise in launching products in different markets, highlighting the importance of hiring experienced personnel [20] Question: Explanation for contract manufacturer's failure to comply with FDA requirements - Management declined to provide details but confirmed that the Incomplete Letter was solely due to issues with the contract manufacturer [22][23] Question: Realism of securing a strategic partner for Re-Tain - Management expressed confidence in the product's capabilities and the need to find the best go-to-market strategy post-investigational studies [27] Question: Timeline for hiring new sales team members - Management confirmed that hiring processes for new sales team members are underway, with expectations to complete them within the current quarter [31] Question: Future cash needs and potential share dilution - Management indicated that various funding options are available, including operating cash flow, loans, and capital raises, but declined to comment on specific plans [33] Question: Clarity on self-imposed milk discard period for Re-Tain - Management explained that the discard period is necessary to avoid impacting cheese manufacturing processes, but it remains less than competitors' requirements [44][45] Question: Explanation for exceeding sales expectations - Management attributed the sales exceeding expectations to effective management practices and a strong commercial team, despite complexities from previous backorder situations [49][50]

PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025. Since the first quarter of 2020, ImmuCell has been providing a preliminary look at its unaudited top line results soon after the close of the quarter and the Company expects to ...

Core Viewpoint - ImmuCell Corporation has received an Incomplete Letter from the FDA regarding its Re-Tain New Animal Drug Application, prompting the company to shift focus towards expanding its First Defense product line, which is expected to drive significant revenue growth [1][2][5]. Group 1: FDA Approval and Manufacturing - ImmuCell received Complete Letters for four out of five Technical Sections required for NADA approval but faced issues with the contract manufacturer related to inspectional deficiencies [2]. - The company had adopted a dual manufacturing strategy to mitigate capital expenditure and technical risks, involving both in-house production and a contract manufacturer [2]. - ImmuCell's facility passed FDA inspection in 2024, but the contract manufacturer's deficiencies led to the current Incomplete Letter [2]. Group 2: Strategic Shift and Investment - Due to delays and the impending expiration of the contract with the manufacturer in March 2026, ImmuCell has decided to pause further investment in Re-Tain and instead increase investment in its First Defense franchise [3][4]. - The First Defense product line is expected to benefit from significant revenue and profit growth, with a focus on the $900 million global market for preventing scours in calves [5]. - ImmuCell plans to repurpose facilities and equipment from the Re-Tain project to enhance First Defense capacity, anticipating a non-cash impairment write-down of approximately $2.3 million [6][7]. Group 3: Market Position and Growth Potential - First Defense has shown strong market performance, with annual revenue growth from approximately $4.4 million to $27.8 million over the past fifteen years, reflecting a compounded growth rate of over 13% per year [7]. - The product line holds a 29% share of the U.S. market for scours prevention and is positioned for international expansion and new product development [5][7]. - Customer feedback and market assessments indicate a favorable environment for further investment in First Defense, which leverages proprietary colostrum hyper-immunization technology [5][7].

Core Insights - ImmuCell Corporation (ICCC) focuses on innovative cattle-health solutions that reduce reliance on traditional antibiotics while addressing calf scours and cow mastitis [1][3][4] Company Overview - ImmuCell is dedicated to creating scientifically proven products that enhance the health and productivity of dairy and beef cattle, targeting significant challenges in dairy systems [3] - The company positions itself as a "non-Pharma pharma" innovator, utilizing novel active ingredients rather than conventional antibiotics or vaccines [4] Product Offerings - **First Defense**: This product provides immediate immunity to newborn calves, helping to prevent scours and supporting herd productivity without requiring dam-level vaccine injections [7][8] - **Re-Tain**: A novel Nisin-based therapy for subclinical mastitis, designed to avoid human-use antibiotics, potentially saving the dairy industry approximately $2 billion annually [9][10] Market Performance - ImmuCell's stock has increased by 17.4% over the past year, outperforming the industry composite's decline of 0.7% and the S&P 500's growth of 15.1% [2] Customer Validation - Positive testimonials from producers and veterinarians highlight the efficacy and ease of administration of First Defense, with reports of scours incidence dropping by 75% after its adoption [11][12][13] Operational Strength - The company has invested in specialized manufacturing infrastructure, operating a USDA facility for First Defense and an FDA facility for Re-Tain, ensuring quality control and scalability [14] - Recent capacity expansions have increased First Defense's annual capacity to approximately $30 million, with further expansion options available [15][16] Financial Performance - For the nine months ending September 30, 2025, ImmuCell reported a net income of $1.8 million, a significant turnaround from a net loss of $2.7 million in the previous year, driven by higher sales and improved margins [17][18] - The gross margin improved to around 43% from 27% year-over-year, indicating enhanced production efficiency [18]

Financial Data and Key Metrics Changes - The company reported a net income of $1.8 million for the nine months ended September 30, 2025, compared to a net loss of $2.7 million for the same period in 2024, marking a $4.5 million improvement [13] - Basic net income per share was approximately $0.20 for the nine-month period ended September 30, 2025, compared to a net loss of $0.34 per share in the prior year [16] - Gross margin as a percentage of product sales increased to 43% during the third quarter of 2025, up from 26% in the same quarter of 2024 [18] Business Line Data and Key Metrics Changes - Total product sales decreased by 8% or $505,000 in the third quarter of 2025 compared to the third quarter of 2024 [16] - Domestic sales increased by 2% in the third quarter of 2025 compared to the same quarter in 2024, and were up 9.5% compared to the second quarter of 2025 [12] - International sales were down during the third quarter of 2025 compared to the same period in 2024, primarily due to timing of shipments and short supply management [12] Market Data and Key Metrics Changes - The U.S. market represented approximately 86% of total sales during the trailing 12-month period ended September 30, 2025 [12] - International sales for the nine-month period ended September 30, 2025, were 15% higher than the same period in the prior year [13] Company Strategy and Development Direction - The company aims to regain customers and expand the use of scour preventatives while exploring new market opportunities more aggressively [11] - The focus is on operational excellence and execution, with a priority on production capacity and quality [14] - The company is awaiting FDA approval for its Retain product, which targets subclinical mastitis, and is conducting investigational product use studies to gather market feedback [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position and the positive changes in the commercial team, emphasizing a shift from managing short supply to winning new customers [26] - The company is focused on maintaining strong production yields and driving growth from existing products while managing cash and inventory effectively [20][31] Other Important Information - The company has undergone significant management transitions, with Oliver Tebukurst appointed as the new President and CEO effective November 1, 2025 [6] - The company has improved its cash position to $3.9 million as of September 30, 2025, from $3.8 million at the end of 2024, while investing in inventory [20] Q&A Session Summary Question: What has changed regarding First Defense and the growth expectations? - Management indicated that they have reached a level of capacity set during the expansion project and have implemented quality measures to ensure predictable manufacturing levels [26] Question: How does the company plan to balance production with cash generation? - The CFO noted that inventory levels have increased to a more desirable level as they approach peak selling season, and they are closely monitoring inventory management [31] Question: What attributed to the margin improvement in Q3? - The CFO attributed the gross margin improvement to enhanced manufacturing performance and a composite price increase of around 6% in 2025 [34]

Core Insights - ImmuCell Corporation reported a significant turnaround in financial performance for the nine-month period ended September 30, 2025, achieving a net income of $1.8 million compared to a net loss of $2.7 million in the same period last year, driven by higher product sales and improved gross margins [4][9]. Product Sales Highlights - Preliminary product sales for Q3 2025 were approximately $5.5 million, reflecting an 8% decrease compared to Q3 2024 [8]. - For the nine-month period ended September 30, 2025, product sales increased by 7% to approximately $20.0 million compared to the same period in 2024 [8]. - Over the twelve-month period ended September 30, 2025, product sales rose by 16% to approximately $27.8 million compared to the previous year [8]. Financial Performance - Gross margin improved to 43% for Q3 2025, up from 26% in Q3 2024, and reached 42.6% for the nine-month period ended September 30, 2025, compared to 27.3% in 2024 [5][9]. - The net loss for Q3 2025 was approximately $140,000, or $0.02 per basic share, compared to a net loss of $702,000, or $0.09 per basic share, in Q3 2024 [9][14]. - Adjusted EBITDA for Q3 2025 was approximately $751,000, significantly up from $196,000 in Q3 2024 [9][17]. Balance Sheet Data - As of September 30, 2025, cash and cash equivalents increased to approximately $3.9 million from $3.8 million as of December 31, 2024 [9][16]. - Net working capital rose to approximately $12.8 million as of September 30, 2025, compared to $10.6 million at the end of 2024 [9][16]. - Stockholders' equity increased to approximately $29.8 million as of September 30, 2025, up from $27.5 million as of December 31, 2024 [10][16]. Product Development - The company is actively developing Re-Tain, a treatment for subclinical mastitis in dairy cows, in partnership with Michigan State University, with ongoing market feedback collection planned through 2025 and into 2026 [6][20].

Core Points - ImmuCell Corporation plans to report unaudited financial results for Q3 2025 on November 13, 2025, after market close [1][3] - A conference call is scheduled for November 14, 2025, at 9:00 AM ET to discuss the financial results [2] - The company anticipates no changes to the preliminary sales results disclosed on October 7, 2025 [3] - An updated Corporate Presentation slide deck will be available after market close on November 13, 2025 [4] Company Overview - ImmuCell Corporation focuses on developing scientifically proven products to enhance the health and productivity of dairy and beef cattle [5] - The company manufactures First Defense, which provides Immediate Immunity™ to newborn calves, and is developing Re-Tain, a treatment for subclinical mastitis in dairy cows [5]